INS and COVID-19: Glucose levels >98.5 mg/dL (AUC 0.852, Sn 83%, Sp 71%, PPV 80%, NPV 76%) and insulin levels >7.4 mUI/mL (AUC 0.950, Sn 94%, Sp 65%, PPV 79%, NPV 89%) were associated with the development of IR in patients with COVID-19 (Table 4).